TScan publishes ALLOHA Cohort C Phase 1 presentation for TSC-101 TCR-T therapy in post-transplant AML, ALL and MDS
PUBT · 06/22 14:33
Share
Listen to the news
- TScan outlined Phase 1 ALLOHA Cohort C data for TSC-101, supporting a planned pivotal study launch in Q2 2026.
- Long-term relapse-free survival favored TSC-101: 100% (2/2) at 3 years, 71% (5/7) at 2 years, 71% (12/17) at 1 year.
- Control-arm relapse-free survival: 0% (0/3) at 3 years, 43% (3/7) at 2 years, 54% (7/13) at 1 year.
- Cohort C used a commercial-ready process, cutting manufacturing time to 12 days from 17 days; 14 patients treated.
- Cash balance USD 128.1 million as of March 31, 2026; management said this funds operations into H2 2027.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TScan Therapeutics Inc. published the original content used to generate this news brief on June 22, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending